drugset / Trial / NCT05952037
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
Timeline
- Start
- 2023-10-23
- Primary completion
- 2026-09-22
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sonrotoclax | Other / unclassified | — | Oral |
| Subject | Zanubrutinib | Small molecule | — | Oral |